imbruvica®
(ibrutinib)
560, 420, 280, 140 mg tablets | 140, 70 mg capsules

Top 5 Facts About IMBRUVICA®

Here's some information to consider when talking to your doctor about IMBRUVICA®.

IMBRUVICA® has helped many people with CLL live longer.[1]

In a clinical trial of 269 adults aged 65 and older with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had not been treated before, 8% of patients taking IMBRUVICA® died versus 16% taking chemotherapy (chlorambucil), after a median follow-up of 28 months.

With a median follow-up of 18 months, 11% of IMBRUVICA® patients had disease progression or died compared to 48% taking the chemotherapy.

IMBRUVICA® may cause side effects.[1]

Serious side effects include bleeding problems (hemorrhage); infections; heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death; high blood pressure (hypertension); decrease in blood cell counts; second primary cancers; and tumor lysis syndrome (TLS).

The most common side effects of IMBRUVICA® include diarrhea, tiredness, muscle and bone pain, rash, and bruising.

IMBRUVICA® works differently than chemotherapy.[1]

IMBRUVICA® works by blocking a protein in your cells called Bruton's tyrosine kinase (BTK). This action helps stop B cells from surviving and multiplying. IMBRUVICA® may help slow the spread of CLL. A relationship between how IMBRUVICA® works and why it helps to treat CLL has not been clearly identified.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend ibrutinib (IMBRUVICA®) as a preferred treatment option for people with CLL.[2]

IMBRUVICA® Insurance Specialists® can help you understand and learn more about insurance coverage and out-of-pocket costs.

Call 1-888-YourSide (1-888-968-7743) for more information.

Now you know—talk to your doctor to see if IMBRUVICA®, the #1 prescribed oral therapy for CLL, is right for you.[3*]

*Based on available IQVIA claims data.

Please review the Important Side Effect Information on the next page. Click here to see the Important Product Information or go to www.imbruvica.com/prescribing-information.

IMPORTANT SIDE EFFECT INFORMATION

Before taking IMBRUVICA® (ibrutinib), tell your healthcare provider about all of your medical conditions, including if you:

- have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
- have bleeding problems
- have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
- have an infection
- have liver problems
- are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®. Tell your healthcare provider if you are pregnant or think you may be pregnant during treatment with IMBRUVICA®.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with IMBRUVICA® and for 1 month after the last dose.
  - **Males** with female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose.
- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

- Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
- Take IMBRUVICA® 1 time a day.
- Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
- Do not open, break or chew IMBRUVICA® capsules.
- Do not cut, crush or chew IMBRUVICA® tablets.
- Take IMBRUVICA® at about the same time each day.
- If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
- If you take too much IMBRUVICA® call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking IMBRUVICA®?

- You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

- **Bleeding problems (hemorrhage) are common** during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.
- **Infections** can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
- **Heart problems.** Serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter), heart failure and death have happened in people treated with IMBRUVICA®, especially in people who have an infection, an increased risk for heart disease, or have had heart

Continued on next page.

IMPORTANT SIDE EFFECT INFORMATION (Continued)

What are the possible side effects of IMBRUVICA® (ibrutinib)? (Continued)

IMBRUVICA® may cause serious side effects (Continued)

rhythm problems in the past. Your heart function will be checked before and during treatment with IMBRUVICA®. Tell your healthcare provider if you get any symptoms of heart problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, swelling of the feet, ankles or legs, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do tests to check your heart and may change your IMBRUVICA® dose.

- **High blood pressure (hypertension).** New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
- **Decrease in blood cell counts.** Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
- **Second primary cancers.** New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
- **Tumor lysis syndrome (TLS).** TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:

- diarrhea
- tiredness
- muscle and bone pain
- rash
- bruising

The most common side effects of IMBRUVICA® in adults with cGVHD include:

- tiredness
- bruising
- diarrhea
- mouth sores (stomatitis)
- muscle spasms
- nausea
- pneumonia

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

Click here to see the Important Product Information or go to www.imbruvica.com/prescribing-information.

USES

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with:

- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
- Waldenström's macroglobulinemia (WM)
- Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy

It is not known if IMBRUVICA® is safe and effective in children.

References:

1. IMBRUVICA® (ibrutinib) Prescribing Information. **2.** Referenced with permission from the *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma* V.4.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May 6, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. **3.** Data on file. Pharmacyclics LLC.

The information in this brochure is not intended to replace the advice of your doctor. If you have any questions about IMBRUVICA® treatment, be sure to contact your healthcare team.

06/22 PRC-09422

pharmacyclics® An AbbVie Company

Janssen